Identification of epitope mimics recognized by CTL reactive to the melanoma/melanocyte-derived peptide MART-1((27-35))

Douglas J. Loftus, Chiara Castelli, Timothy M. Clay, Paola Squarcina, Francesco M. Marincola, Michael I. Nishimura, Giorgio Parmiani, Ettore Appella, Licia Rivoltini

Research output: Contribution to journalArticle

145 Citations (Scopus)

Abstract

CTL reactivity to the epitope MART-1((27-35)) of the melanoma (self) antigen MART-1/melan A is frequently observed in tumor-infiltrating lymphocytes and may be readily elicited from the peripheral blood of melanoma patients that express HLA-A*0201. Available data suggest that these observations contrast with those made for other HLA-A*0201-presented melanoma self antigens regrading the regularity of observed CTL responses. Based of preliminary findings, we hypothesized that the CTL response to MART- 1 might be augmented in part by T cell encounters with peptides derived from sources other than MART-1, which show sequence similarity to MART-1((27- 35)). To test this idea, a protein database search for potential MART-1 epitope mimics was done using criteria developed from analyses of effector recognition of singly-substituted peptide analogues of MART-1((27-35)). Synthetic peptides were made for a portion of the sequences retrieve; 12/40 peptides tested were able to sensitive target cells for lysis by one or more ant-MART-1 effectors. The peptides recognized corresponds to sequences occurring in a variety of proteins of viral, bacterial, and human (self) origin. One peptide derives from glycoprotein C of the common pathogen HSV- 1; cells infected with recombinant vaccinia virus encoding native glycoprotein C were lysed by anti-MART-1 effectors. Our results overall indicate that sequences conforming to the A2.1 binding motif and possessing features essential to recognition by anti-MART-1 CTL, occur frequently in proteins. These findings further suggest that T cells might encounter a variety of such sequences in vivo, and that epitope mimicry may play a role in modulating the CTL response to MART-1((27-35)).

Original languageEnglish
Pages (from-to)647-657
Number of pages11
JournalJournal of Experimental Medicine
Volume184
Issue number2
Publication statusPublished - Aug 1 1996

Fingerprint

Melanocytes
Epitopes
Melanoma
Peptides
Melanoma-Specific Antigens
Autoantigens
MART-1 Antigen
T-Lymphocytes
Tumor-Infiltrating Lymphocytes
Protein Databases
Bacterial Proteins
Ants
Vaccinia virus
Human Herpesvirus 1
Viral Proteins
Proteins

ASJC Scopus subject areas

  • Immunology

Cite this

Identification of epitope mimics recognized by CTL reactive to the melanoma/melanocyte-derived peptide MART-1((27-35)). / Loftus, Douglas J.; Castelli, Chiara; Clay, Timothy M.; Squarcina, Paola; Marincola, Francesco M.; Nishimura, Michael I.; Parmiani, Giorgio; Appella, Ettore; Rivoltini, Licia.

In: Journal of Experimental Medicine, Vol. 184, No. 2, 01.08.1996, p. 647-657.

Research output: Contribution to journalArticle

Loftus, DJ, Castelli, C, Clay, TM, Squarcina, P, Marincola, FM, Nishimura, MI, Parmiani, G, Appella, E & Rivoltini, L 1996, 'Identification of epitope mimics recognized by CTL reactive to the melanoma/melanocyte-derived peptide MART-1((27-35))', Journal of Experimental Medicine, vol. 184, no. 2, pp. 647-657.
Loftus, Douglas J. ; Castelli, Chiara ; Clay, Timothy M. ; Squarcina, Paola ; Marincola, Francesco M. ; Nishimura, Michael I. ; Parmiani, Giorgio ; Appella, Ettore ; Rivoltini, Licia. / Identification of epitope mimics recognized by CTL reactive to the melanoma/melanocyte-derived peptide MART-1((27-35)). In: Journal of Experimental Medicine. 1996 ; Vol. 184, No. 2. pp. 647-657.
@article{623ce193d91e42abb86668c6c71aad25,
title = "Identification of epitope mimics recognized by CTL reactive to the melanoma/melanocyte-derived peptide MART-1((27-35))",
abstract = "CTL reactivity to the epitope MART-1((27-35)) of the melanoma (self) antigen MART-1/melan A is frequently observed in tumor-infiltrating lymphocytes and may be readily elicited from the peripheral blood of melanoma patients that express HLA-A*0201. Available data suggest that these observations contrast with those made for other HLA-A*0201-presented melanoma self antigens regrading the regularity of observed CTL responses. Based of preliminary findings, we hypothesized that the CTL response to MART- 1 might be augmented in part by T cell encounters with peptides derived from sources other than MART-1, which show sequence similarity to MART-1((27- 35)). To test this idea, a protein database search for potential MART-1 epitope mimics was done using criteria developed from analyses of effector recognition of singly-substituted peptide analogues of MART-1((27-35)). Synthetic peptides were made for a portion of the sequences retrieve; 12/40 peptides tested were able to sensitive target cells for lysis by one or more ant-MART-1 effectors. The peptides recognized corresponds to sequences occurring in a variety of proteins of viral, bacterial, and human (self) origin. One peptide derives from glycoprotein C of the common pathogen HSV- 1; cells infected with recombinant vaccinia virus encoding native glycoprotein C were lysed by anti-MART-1 effectors. Our results overall indicate that sequences conforming to the A2.1 binding motif and possessing features essential to recognition by anti-MART-1 CTL, occur frequently in proteins. These findings further suggest that T cells might encounter a variety of such sequences in vivo, and that epitope mimicry may play a role in modulating the CTL response to MART-1((27-35)).",
author = "Loftus, {Douglas J.} and Chiara Castelli and Clay, {Timothy M.} and Paola Squarcina and Marincola, {Francesco M.} and Nishimura, {Michael I.} and Giorgio Parmiani and Ettore Appella and Licia Rivoltini",
year = "1996",
month = "8",
day = "1",
language = "English",
volume = "184",
pages = "647--657",
journal = "Journal of Experimental Medicine",
issn = "0022-1007",
publisher = "Rockefeller University Press",
number = "2",

}

TY - JOUR

T1 - Identification of epitope mimics recognized by CTL reactive to the melanoma/melanocyte-derived peptide MART-1((27-35))

AU - Loftus, Douglas J.

AU - Castelli, Chiara

AU - Clay, Timothy M.

AU - Squarcina, Paola

AU - Marincola, Francesco M.

AU - Nishimura, Michael I.

AU - Parmiani, Giorgio

AU - Appella, Ettore

AU - Rivoltini, Licia

PY - 1996/8/1

Y1 - 1996/8/1

N2 - CTL reactivity to the epitope MART-1((27-35)) of the melanoma (self) antigen MART-1/melan A is frequently observed in tumor-infiltrating lymphocytes and may be readily elicited from the peripheral blood of melanoma patients that express HLA-A*0201. Available data suggest that these observations contrast with those made for other HLA-A*0201-presented melanoma self antigens regrading the regularity of observed CTL responses. Based of preliminary findings, we hypothesized that the CTL response to MART- 1 might be augmented in part by T cell encounters with peptides derived from sources other than MART-1, which show sequence similarity to MART-1((27- 35)). To test this idea, a protein database search for potential MART-1 epitope mimics was done using criteria developed from analyses of effector recognition of singly-substituted peptide analogues of MART-1((27-35)). Synthetic peptides were made for a portion of the sequences retrieve; 12/40 peptides tested were able to sensitive target cells for lysis by one or more ant-MART-1 effectors. The peptides recognized corresponds to sequences occurring in a variety of proteins of viral, bacterial, and human (self) origin. One peptide derives from glycoprotein C of the common pathogen HSV- 1; cells infected with recombinant vaccinia virus encoding native glycoprotein C were lysed by anti-MART-1 effectors. Our results overall indicate that sequences conforming to the A2.1 binding motif and possessing features essential to recognition by anti-MART-1 CTL, occur frequently in proteins. These findings further suggest that T cells might encounter a variety of such sequences in vivo, and that epitope mimicry may play a role in modulating the CTL response to MART-1((27-35)).

AB - CTL reactivity to the epitope MART-1((27-35)) of the melanoma (self) antigen MART-1/melan A is frequently observed in tumor-infiltrating lymphocytes and may be readily elicited from the peripheral blood of melanoma patients that express HLA-A*0201. Available data suggest that these observations contrast with those made for other HLA-A*0201-presented melanoma self antigens regrading the regularity of observed CTL responses. Based of preliminary findings, we hypothesized that the CTL response to MART- 1 might be augmented in part by T cell encounters with peptides derived from sources other than MART-1, which show sequence similarity to MART-1((27- 35)). To test this idea, a protein database search for potential MART-1 epitope mimics was done using criteria developed from analyses of effector recognition of singly-substituted peptide analogues of MART-1((27-35)). Synthetic peptides were made for a portion of the sequences retrieve; 12/40 peptides tested were able to sensitive target cells for lysis by one or more ant-MART-1 effectors. The peptides recognized corresponds to sequences occurring in a variety of proteins of viral, bacterial, and human (self) origin. One peptide derives from glycoprotein C of the common pathogen HSV- 1; cells infected with recombinant vaccinia virus encoding native glycoprotein C were lysed by anti-MART-1 effectors. Our results overall indicate that sequences conforming to the A2.1 binding motif and possessing features essential to recognition by anti-MART-1 CTL, occur frequently in proteins. These findings further suggest that T cells might encounter a variety of such sequences in vivo, and that epitope mimicry may play a role in modulating the CTL response to MART-1((27-35)).

UR - http://www.scopus.com/inward/record.url?scp=0029788301&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0029788301&partnerID=8YFLogxK

M3 - Article

C2 - 8760818

AN - SCOPUS:0029788301

VL - 184

SP - 647

EP - 657

JO - Journal of Experimental Medicine

JF - Journal of Experimental Medicine

SN - 0022-1007

IS - 2

ER -